Thrombotic and bleeding complications associated with chemotherapy

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 808-817

  McMahon, Brandon J ^a   Kwaan, Hau C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

adverse drug reactions; bleeding; cancer; chemotherapy; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; BEVACIZUMAB; CISPLATIN; DEXAMETHASONE; ELTROMBOPAG; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PREDNISONE; RECOMBINANT THROMBOPOIETIN; RETINOIC ACID; ROMIPLOSTIM; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; AGE; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; COLORECTAL CANCER; COMORBIDITY; CYTOPENIA; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM CANCER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY CARCINOMA; KIDNEY INFARCTION; LEUKEMIA REMISSION; LEUKOENCEPHALOPATHY; LIVER CELL CARCINOMA; LIVER INJURY; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUNG CANCER; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM TUMOR; MANTLE CELL LYMPHOMA; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUROTOXICITY; OVARY CANCER; PANCREAS CANCER; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOIC ACID SYNDROME; RISK FACTOR; SOLID TUMOR; SPLEEN INFARCTION; STOMACH CANCER; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOSIS; UPREGULATION; VEIN OCCLUSION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; HEMORRHAGE; HUMANS; NEOPLASMS; RISK FACTORS; THROMBOSIS;

EID: 84868527006     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328885     Document Type: Article

References (107)

1. Trousseau A. Phlegmatia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris. Paris Balliere: 1865; 654 712
2. White R. H., Chew H. K., Zhou H., et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med: 2005; 165 15 1782 1787 (Pubitemid 41138968)
3. Khorana A. A., Francis C. W., Culakova E., Lyman G. H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer: 2005; 104 12 2822 2829 (Pubitemid 41798294)
4. Zangari M., Barlogie B., Thertulien R., et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma: 2003; 4 1 32 35 (Pubitemid 36826874)
5. Escudier S. M., Kantarjian H. M., Estey E. H. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma: 1996; 20 5-6 435 439 (Pubitemid 26096049)
6. Colović M., Miljić P., Colović N., Janković G., Stojković M. Reversible portal vein thrombosis complicating induction therapy of acute promyelocytic leukemia. Thromb Res: 2001; 101 2 101 103 (Pubitemid 32141184)
7. Goldschmidt N., Gural A., Ben Yehuda D. Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia. Leuk Lymphoma: 2003; 44 8 1433 1437 (Pubitemid 36764302)
8. Breccia M., Avvisati G., Latagliata R., et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia: 2007; 21 1 79 83 (Pubitemid 44921838)
9. Tallman M. S., Abutalib S. A., Altman J. K. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost: 2007; 33 4 330 338 (Pubitemid 46878105)
10. Brown J. E., Olujohungbe A., Chang J., et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol: 2000; 110 4 1010 1012
11. Hashimoto S., Koike T., Tatewaki W., et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia: 1994; 8 7 1113 1115 (Pubitemid 24224512)
12. Wang J., Weiss I., Svoboda K., Kwaan H. C. Thrombogenic role of cells undergoing apoptosis. Br J Haematol: 2001; 115 2 382 391 (Pubitemid 34203507)
13. Montesinos P., Sanz M. A. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pathema group and review of the literature. Mediterr J Hematol Infect Dis: 2011; 3 1 e2011059
14. Rego E. M., De Santis G. C. Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment. Mediterr J Hematol Infect Dis: 2011; 3 1 e2011048
15. De Botton S., Dombret H., Sanz M., et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood: 1998; 92 8 2712 2718 (Pubitemid 28469083)
16. Kerbel R. S. Tumor angiogenesis. N Engl J Med: 2008; 358 19 2039 2049 (Pubitemid 351656458)
17. Kuenen B. C. Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb: 2003; 33 01 13 14 (Pubitemid 37490520)
18. Yang R., Thomas G. R., Bunting S., et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol: 1996; 27 6 838 844 (Pubitemid 26000416)
19. Nalluri S. R., Chu D., Keresztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA: 2008; 300 19 2277 2285
20. Hurwitz H. I., Saltz L. B., Van Cutsem E., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol: 2011; 29 13 1757 1764
21. Ranpura V., Hapani S., Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA: 2011; 305 5 487 494
22. Scappaticci F. A., Skillings J. R., Holden S. N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst: 2007; 99 16 1232 1239 (Pubitemid 47299901)
23. Ranpura V., Hapani S., Chuang J., Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol: 2010; 49 3 287 297
24. Hurwitz H. I., Fehrenbacher L., Hainsworth J. D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol: 2005; 23 15 3502 3508
25. Kabbinavar F. F., Hambleton J., Mass R. D., Hurwitz H. I., Bergsland E., Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol: 2005; 23 16 3706 3712
26. Cooney M. M., Tserng K. Y., Makar V., et al. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol: 2005; 55 3 295 300 (Pubitemid 40142895)
27. Kuenen B. C., Rosen L., Smit E. F., et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol: 2002; 20 6 1657 1667 (Pubitemid 34260548)
28. Zangari M., Fink L. M., Elice F., Zhan F., Adcock D. M., Tricot G. J. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol: 2009; 27 29 4865 4873
29. Escudier B., Eisen T., Stadler W. M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med: 2007; 356 2 125 134 (Pubitemid 46089673)
30. Siu L. L., Awada A., Takimoto C. H., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res: 2006; 12 1 144 151 (Pubitemid 43166188)
31. Moore R. A., Adel N., Riedel E., et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol: 2011; 29 25 3466 3473
32. Numico G., Garrone O., Dongiovanni V., et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer: 2005; 103 5 994 999 (Pubitemid 40270076)
33. Starling N., Rao S., Cunningham D., et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol: 2009; 27 23 3786 3793
34. Czaykowski P. M., Moore M. J., Tannock I. F. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol: 1998; 160 6 Pt 1 2021 2024 (Pubitemid 128703605)
35. Al-Batran S. E., Hartmann J. T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol: 2008; 26 9 1435 1442
36. Artero A., Tarín J. J., Cano A. The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis. Semin Thromb Hemost: 2012; 38 8 797 807
37. Ravandi F., Kantarjian H. Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia. Nat Rev Clin Oncol: 2012; 9 6 310 311
38. Castaigne S., Pautas C., Terré C., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet: 2012; 379 9825 1508 1516
39. Jabbour E., Garcia-Manero G., Cortes J., et al. Twice-daily fludarabine and cytarabine combination with or without gemtuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk: 2012; 12 4 244 251
40. Estey E. Treatment of AML: resurrection for gemtuzumab ozogamicin? Lancet: 2012; 379 9825 1468 1469
41. Shulman H. M., Gown A. M., Nugent D. J. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol: 1987; 127 3 549 558 (Pubitemid 17089816)
42. Larson R. A., Sievers E. L., Stadtmauer E. A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer: 2005; 104 7 1442 1452 (Pubitemid 41356159)
43. McKoy J. M., Angelotta C., Bennett C. L., et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res: 2007; 31 5 599 604 (Pubitemid 46578145)
44. Jorgensen K. A., Sorensen P., Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol: 1982; 68 1 39 42 (Pubitemid 12082255)
45. Frankfurt O., Rosen S. T. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol: 2004; 16 6 553 563 (Pubitemid 39482974)
46. Mitsiades N., Mitsiades C. S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood: 2002; 99 12 4525 4530 (Pubitemid 34627223)
47. Bennett C. L., Spiegel D. M., Macdougall I. C., et al. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR) on hemostasis and thrombosis. Semin Thromb Hemost: 2012; 38 8 783 796
48. Barbui T., Finazzi G., Grassi A., Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factorsa meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost: 1996; 75 2 368 371
49. Topcuoglu P., Arat M., Dalva K., Ozcan M. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant: 2004; 33 2 171 176 (Pubitemid 38180929)
50. LeBlanc R., Roy J., Demers C., Vu L., Cantin G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant: 1999; 23 10 991 996 (Pubitemid 29250842)
51. Kuter D. J., Bussel J. B., Lyons R. M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet: 2008; 371 9610 395 403 (Pubitemid 351181334)
52. Cheng G., Saleh M. N., Marcher C., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet: 2011; 377 9763 393 402
53. Grace R. F., Dahlberg S. E., Neuberg D., et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol: 2011; 152 4 452 459
54. Rubinstein L. J., Herman M. M., Long T. F., Wilbur J. R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer: 1975; 35 2 291 305
55. Lai R., Abrey L. E., Rosenblum M. K., DeAngelis L. M. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology: 2004; 62 3 451 456 (Pubitemid 38200859)
56. Mahadeo K. M., Dhall G., Panigrahy A., Lastra C., Ettinger L. J. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. Pediatr Hematol Oncol: 2010; 27 1 46 52
57. Quinn C. T., Kamen B. A. A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med: 1996; 44 9 522 530 (Pubitemid 126820700)
58. Silverstein F. S., Johnston M. V. A model of methotrexate encephalopathy: neurotransmitter and pathologic abnormalities. J Child Neurol: 1986; 1 4 351 357 (Pubitemid 17207941)
59. Hanson N. Q., Aras O., Yang F., Tsai M. Y. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem: 2001; 47 4 661 666 (Pubitemid 32275808)
60. Quinn C. T., Griener J. C., Bottiglieri T., Kamen B. A. Methotrexate, homocysteine, and seizures. J Clin Oncol: 1998; 16 1 393 394
61. Bennett C. L., Schumock G. T., Desai A. A., et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med: 2002; 113 7 603 606 (Pubitemid 35379916)
62. Rajkumar S. V., Blood E., Vesole D., Fonseca R., Greipp P. R. Eastern Cooperative Oncology Group Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol: 2006; 24 3 431 436 (Pubitemid 46630462)
63. Weber D., Rankin K., Gavino M., Delasalle K., Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol: 2003; 21 1 16 19
64. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood: 2001; 98 2 492 494
65. Prince H. M., Mileshkin L., Roberts A., et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res: 2005; 11 15 5504 5514 (Pubitemid 41060827)
66. Wu P., Davies F. E., Horton C., et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma: 2006; 47 11 2335 2338 (Pubitemid 44768426)
67. Zervas K., Dimopoulos M. A., Hatzicharissi E., et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol: 2004; 15 1 134 138 (Pubitemid 38139615)
68. Facon T., Mary J. Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet: 2007; 370 9594 1209 1218 (Pubitemid 47516593)
69. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet: 2006; 367 9513 825 831 (Pubitemid 43363369)
70. Offidani M., Marconi M., Corvatta L., Olivieri A., Catarini M., Leoni P. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica: 2003; 88 12 1432 1433 (Pubitemid 38029733)
71. Rajkumar S. V., Hayman S., Gertz M. A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol: 2002; 20 21 4319 4323 (Pubitemid 35266292)
72. Cavo M., Zamagni E., Cellini C., et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood: 2002; 100 6 2272 2273 (Pubitemid 35001274)
73. Barlogie B., Kyle R. A., Anderson K. C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol: 2006; 24 6 929 936 (Pubitemid 46638847)
74. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc: 2005; 80 12 1568 1574 (Pubitemid 41747058)
75. List A., Kurtin S., Roe D. J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med: 2005; 352 6 549 557 (Pubitemid 40204668)
76. Zonder J. A., Barlogie B., Durie B. G., McCoy J., Crowley J., Hussein M. A. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood: 2006; 108 1 403, author reply 404 (Pubitemid 43990659)
77. Rajkumar S. V., Jacobus S., Callander N. S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol: 2010; 11 1 29 37
78. Zangari M., Fink L., Zhan F., Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk: 2011; 11 2 228 236
79. Miller S. C., Huang R., Sakamuru S., et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol: 2010; 79 9 1272 1280
80. Li Y. D., Ye B. Q., Zheng S. X., et al. NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem: 2009; 284 7 4473 4483
81. Morgan E. N., Pohlman T. H., Vocelka C., et al. Nuclear factor kappaB mediates a procoagulant response in monocytes during extracorporeal circulation. J Thorac Cardiovasc Surg: 2003; 125 1 165 171 (Pubitemid 36120283)
82. Lonial S., Richardson P. G., San Miguel J., et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol: 2008; 143 2 222 229
83. Hiroi T., Deming C. B., Zhao H., et al. Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors. Arterioscler Thromb Vasc Biol: 2009; 29 10 1587 1593
84. Palumbo A., Rajkumar S. V., Dimopoulos M. A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia: 2008; 22 2 414 423 (Pubitemid 351255436)
85. Carrier M., Le Gal G., Tay J., Wu C., Lee A. Y. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost: 2011; 9 4 653 663
86. Khorana A. A., Connolly G. C. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol: 2009; 27 29 4839 4847
87. Stein P. D., Beemath A., Meyers F. A., Skaf E., Sanchez J., Olson R. E. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med: 2006; 119 1 60 68 (Pubitemid 43117468)
88. Weiss R. B., Tormey D. C., Holland J. F., Weinberg V. E. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep: 1981; 65 7-8 677 679 (Pubitemid 11046788)
89. Levine M. N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med: 1988; 318 7 404 407 (Pubitemid 18044179)
90. von Tempelhoff G. F., Dietrich M., Hommel G., Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol: 1996; 14 9 2560 2568 (Pubitemid 26300124)
91. Goodnough L. T., Saito H., Manni A., Jones P. K., Pearson O. H. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer: 1984; 54 7 1264 1268 (Pubitemid 14003521)
92. Rivkin S. E., Green S., Metch B., et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol: 1994; 12 10 2078 2085 (Pubitemid 24356024)
93. Amir E., Seruga B., Niraula S., Carlsson L., Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst: 2011; 103 17 1299 1309
94. Scappaticci F. A., Skillings J. R., Holden S. N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst: 2007; 99 16 1232 1239 (Pubitemid 47299901)
95. Nalluri S. R., Chu D., Keresztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA: 2008; 300 19 2277 2285
96. Higa G. M., Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther: 2009; 9 7 999 1007
97. Kirwan C. C., McDowell G., McCollum C. N., Kumar S., Byrne G. J. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer: 2008; 99 7 1000 1006
98. Mukherjee S. D., Swystun L. L., Mackman N., et al. Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients. Pathophysiol Haemost Thromb: 2010; 37 2-4 88 97
99. Kristinsson S. Y. Thrombosis in multiple myeloma. Hematology (Am Soc Hematol Educ Program): 2010; 2010 437 444
100. Kristinsson S. Y., Björkholm M., Schulman S., Landgren O. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. Semin Hematol: 2011; 48 1 46 54
101. Zangari M., Berno T., Zhan F., Tricot G., Fink L. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost: 2012; 38 8 768 779
102. Kristinsson S. Y., Pfeiffer R. M., Bjorkholm M., Schulman S., Landgren O. Thrombosis is associated with inferior survival in multiple myeloma. Haematologica: 2012;; April 17. 10.3324/haematol.2012.064444 [Epub ahead of print]
103. Maxwell W. D., Bennett C. L. Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost: 2012; 38 8 759 767
104. Hulin C., Facon T., Rodon P., et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol: 2009; 27 22 3664 3670
105. Offidani M., Corvatta L., Marconi M., et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J: 2004; 5 4 312 317 (Pubitemid 39214208)
106. Richardson P. G., Mitsiades C., Hideshima T., Anderson K. C. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther: 2006; 6 8 1165 1173 (Pubitemid 44304685)
107. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med: 2007; 357 21 2123 2132 (Pubitemid 350146107)